ResMed Logo

About us

Changing lives with every breath

“Our new brand will be front and center as we continue making a difference to patients, to physicians, and to healthcare systems. It’s exciting and it’s just the first step in what will be a landmark year for ResMed, with launches of game-changing products and solutions.”

Mick Farrell, CEO ResMed

 

At ResMed, we believe that every breath is a gift.
And from the day we began pioneering sleep apnea treatment in 1989, our purpose has been to spread awareness and deliver life-changing products and solutions to patients suffering from sleep-disordered breathing and other respiratory conditions.

More than twenty-five years later, we’re unveiling a new brand that reinforces our stance as an industry leader and, more importantly, our commitment to improving lives.
To reflect our updated brand, we’ve refreshed our company website for the US and updated our logo.

The blue-to-red pulse curve not only symbolizes the transition from deoxygenated to oxygenated blood with every breath and beat of the heart, but it represents the very reason we are here today as an organization; to make every breath another chance for positive change.

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases.
ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.

 

Our Vision and Our Mission

Our Vision is to be the global solutions leader for SDB, COPD and other major chronic diseases. Our Mission is to improve the quality of life for patients, prevent progression of chronic diseases, and reduce overall healthcare system costs.

Aims and objectives

We are a global leader in the development, manufacturing and marketing of innovative medical products for the treatment and management of respiratory disorders, with a focus on sleep-disordered breathing.

We sell a comprehensive range of products in more than 100 countries worldwide through direct offices and a network of distributors.

We are committed to advancing innovative technology in sleep and respiratory medicine and commercializing innovative products incorporating these technologies on a global basis. In reaching our goals, we will at all times act ethically in dealing with both customers and employees.

 

The ResMed story

In 1981 Professor Colin Sullivan and colleagues at the University of Sydney described and developed nasal continuous positive airway pressure (CPAP), the first successful, noninvasive treatment for obstructive sleep apnea (OSA).

After publication of the initial successful results in Lancet, Sullivan, who had patented the technology, attempted to find a compatible partner to help commercialize the sleep technology. In 1986, Chris Lynch, who was then working with Dr. Peter Farrell, who was Managing Director of the Baxter Centre for Medical Research and also Vice President of R&D for Baxter Healthcare, Japan, met with Sullivan and recommended that Peter also meet with him to hear his story. The result was that in 1987 Farrell, on behalf of Baxter, invested in Sullivan’s technology to further evolve the prototype and subsequently undertake clinical trials of the CPAP device on a group of patients with severe sleep apnea.

In 1988, for a variety of reasons, Baxter decided not to enter the sleep apnea market and in 1989 Dr. Farrell founded ResMed in order to affect a management buyout of the Sullivan sleep technology from Baxter. After the MBO was completed ResMed proceeded to commercialize Sullivan’s prototype CPAP device to allow scalable device production and, therefore, effectively treat a critical mass of patients with OSA, the major manifestation of sleep-disordered breathing (SDB).

From its early operations, in late 1989, ResMed grew dramatically during the next 25 years. Revenues for the first fiscal year in 1990 were less than $1 million and there were only 9 employees. As of December 2014, RMD employs well over 4000 people globally, operates in 100 countries, has revenues of approximately $1.6 billion and the current market capitalization for RMD on the New York Stock Exchange is close to $7.5 billion.

The executive team

Our friendly, smart and dynamic executive team is dedicated to providing the right solutions with the right results, every time.

ResMed animated logo

At ResMed, we believe that every breath is a gift. And from the day we began pioneering sleep apnea treatment in 1989, our purpose has been to spread awareness and deliver life-changing products and solutions to patients suffering from sleep-disordered breathing and other respiratory conditions.

Other videos

ResMed animated logo

At ResMed, we believe that every breath is a gift. And fr